LITS

Lite Strategy, Inc.

$0.96

0.86%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Source: Yahoo Finance
AI summary

Price & performance

1M-29.9%
3M+0.8%
YTD-37.2%
1Y-53.7%
52-week range—
Beta1.03
Full chart and returns against a benchmark

Q-Score

35/ 100

Quality against peers; 50 is the peer median.

Growth37
Risk50
Performance29
Valuation47
Profitability35
Leverage32
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue—
Net income-$71.2M
Net margin—
Historical fundamentals

Red flags in filings

1active red flag
Auditor changeDec 5, 2025
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

LITSIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B0.506.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Nov 13next report, before the open
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate